Improving extracorporeal shock wave therapy with 904 or 905 nm pulsed, high power laser pretreatment

Christoph Schmitz

Extracorporeal Shock Wave Research Unit, Chair of Neuroanatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany

Extracorporeal shock wave therapy (ESWT) is a well investigated and widely used treatment modality for a number of musculoskeletal disorders. A limitation of ESWT is its potential painfulness at higher, clinically relevant energy flux density (EFD), which may limit its applicability and, thus, effectiveness. Various studies in the literature demonstrated that neither application of a higher number of extracorporeal shock waves with lower EFD nor use of local anesthesia may solve this problem. Based on the results of several other studies in the literature it is hypothesized here that in patients suffering from musculoskeletal disorders that can be treated with ESWT, pretreatment with a pulsed, high power laser with a wavelength of 904 or 905 nanometers (hereafter: "laser pretreatment") does not only allow to apply higher EFDs in subsequent ESWT but actually results in faster and/or better treatment outcome than ESWT without laser pretreatment. Accordingly, it is hypothesized here that combining ESWT with laser pretreatment leads to synergistic effects and, thus, is superior to either treatment modality alone. Confirming this hypothesis in preclinical and clinical research may raise significance and increase the use of ESWT in physical and rehabilitation medicine, with immediate benefit for patients.

Keywords: extracorporeal shock wave therapy; ESWT, laser therapy; musculoskeletal system, rehabilitation

Correspondence
Dr. Christoph Schmitz MD
Extracorporeal Shock Wave Research Unit
Chair of Neuroanatomy
Institute of Anatomy
Faculty of Medicine
LMU Munich
Munich
Germany
Phone: +49-89-2180-72620
Fax: +49-89-2180-72683
E-mail: christoph_schmitz@med.uni-muenchen.de
ABSTRACT

Extracorporeal shock wave therapy (ESWT) is a well investigated and widely used treatment modality for a number of musculoskeletal disorders. A limitation of ESWT is its potential painfulness at higher, clinically relevant energy flux density (EFD), which may limit its applicability and, thus, effectiveness. Various studies in the literature demonstrated that neither application of a higher number of extracorporeal shock waves with lower EFD nor use of local anesthesia may solve this problem. Based on the results of several other studies in the literature it is hypothesized here that in patients suffering from musculoskeletal disorders that can be treated with ESWT, pretreatment with a pulsed, high power laser with a wavelength of 904 or 905 nanometers (hereafter: "laser pretreatment") does not only allow to apply higher EFDs in subsequent ESWT but actually results in faster and/or better treatment outcome than ESWT without laser pretreatment. Accordingly, it is hypothesized here that combining ESWT with laser pretreatment leads to synergistic effects and, thus, is superior to either treatment modality alone. Confirming this hypothesis in preclinical and clinical research may raise significance and increase the use of ESWT in physical and rehabilitation medicine, with immediate benefit for patients.

Keywords: extracorporeal shock wave therapy; ESWT, laser therapy; musculoskeletal system, rehabilitation
INTRODUCTION

Significance of extracorporeal shock wave therapy
Extracorporeal shock wave therapy (ESWT) is a well investigated and widely used non-pharmacological, non-surgical treatment modality for a number of musculoskeletal disorders including rotator cuff pathology with or without calcification, tennis elbow, knee osteoarthritis, Achilles tendinopathy, plantar fasciopathy, myofascial trigger points and fracture nonunions [1-5]. The Physiotherapy Evidence Database PEDro [6] (with over 48.000 randomized controlled trials (RCTs), systematic reviews and clinical practice guidelines currently the largest independent database in the field of physical and rehabilitation medicine) has listed more than 150 RCTs on ESWT since its inception until today. For certain conditions, RCTs on ESWT are the predominant type of RCT listed in PEDro and/or obtained the highest PEDro quality scores among all investigated treatment modalities [3].

A typical treatment protocol of ESWT comprises three treatment sessions at 1-week intervals, with 2000 extracorporeal shock waves (ESWs) per treatment session applied at a certain energy flux density (EFD) (explained in the next paragraph) [3].

Basic physical principles of extracorporeal shock waves
Extracorporeal shock waves are single acoustic impulses with an initial high positive peak pressure (Pp) between 10 and 100 Megapascal (MPa) reached in less than one microsecond (µs) [7] (note that 10 MPa (100 Bar) is the pressure in a water depth of 1009 meters, and 100 MPa (1000 Bar) is the pressure in a water depth of 10.187 meters). The positive pressure is followed by a low tensile pressure (with negative peak pressure (Pn) up to -20 MPa [8]) lasting for a few µs [3,9-11]. For all that is known, both the positive (associated with stress) and negative (associated with cavitation) components of ESWs are responsible for therapeutic bioeffects [12,13]. The life cycle of an extracorporeal shock wave is approximately 5-20 µs [7-11].

A key characteristic of ESWs is their energy flux density (EFD), which is calculated as the integral of pressure over time [7-11]. The EDF related to the positive pressure is EFD+, the EFD related to the negative pressure is EFD-, and the total EFD is the sum of EFD+ and EFD- [7,8,10,11].

Radial ESWs differ from focused ESWs in the penetration depth into the tissue, a number of physical characteristics and the technology for generating them [3]. Radial ESWs are not real shock waves in the strict physical sense [14]. Focused ESWs may or may not be real shock waves in the strict physical sense, depending on their pressure characteristics and the way they are generated [14,15]. Compared to measurements performed in water, penetration of focused ESWs through biological tissue was demonstrated to cause a reduction in both Pp and Pn as well as an increased rise time (i.e., the time between 10% of Pp and 90% of Pp) [16]. In consequence, one should keep in mind that those focused ESWs that are real shock waves in the strict physical sense when measured in water may lose this characteristic in biological tissue. On the other hand, the rise time of the applied ESWs is possibly rather insignificant for the effectiveness of ESWT [17].

Mode of action of extracorporeal shock waves on musculoskeletal tissue
The release of substance P (one of the body's neurotransmitter of pain and heat), calcitonin gene-related peptide and other inflammation mediators from afferent nerve fibers is generally referred to as neurogenic inflammation [18-20]. The latter was demonstrated being involved in the pathogenesis of tendinopathies such as tennis elbow and Achilles tendinopathy [21,22]. A key working mechanism of ESWs on musculoskeletal tissue is overstimulation of substance P nerve fibers, which depletes presynaptic substance P [23]. As a result, the nerves are apparently unable to report pain for an extended period of time, which leads to reduction in sensation of pain and blockade of neurogenic inflammation. Furthermore, ESWs can lead in the treated tissue to a stronger expression of growth factors such as bone morphogenetic proteins (BMPs), endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) [24-26] as well as to activation of cells that are involved in tissue regeneration [27-29].

Current limitations of extracorporeal shock wave therapy
Several studies (RCTs, meta-analyses and a recent systematic review) demonstrated superiority of ESWT performed at higher EFD compared with ESWT performed at lower EFD [3,30-32]. Unfortunately, due to its action on substance P nerve fibers ESWT may become very painful at higher, clinically relevant EFD, which may limit its applicability and, thus, effectiveness.

A key study on focused extracorporeal shock wave therapy (fESWT) for chronic calcifying tendonitis of the shoulder demonstrated that two treatment sessions with 6000 focused ESWs each with EFD+ = 0.08 mJ/mm² resulted in worse clinical outcome than two treatment sessions with 1500 focused ESWs each with EFD+ = 0.32 mJ/mm² (in both cases the cumulative EFD+ was 0.96 J/mm²) [33]. In line with these results, a very recent study on radial extracorporeal shock wave therapy (rESWT) for knee osteoarthritis demonstrated that four treatment sessions with 4000 radial ESWs each with EFD+ = 0.12 mJ/mm² resulted in worse clinical outcome than four treatment sessions with 2000 radial ESWs each with EFD+ = 0.24 mJ/mm² (in both cases the cumulative EFD+ was 1.92 J/mm²) [34]. Accordingly, applying a higher number of ESWs with lower EFD does not solve the problem that ESWT may become very painful at higher EFD, potentially limiting its applicability and, thus, effectiveness.

In several recent studies this problem was circumvented by applying the individual, maximum EFD a patient could tolerate [35-37]. However, this may result in increased interindividual differences in the amount of shock wave
energy applied in the same study, with potential impact on interindividual differences in treatment success.

Other authors have approached this problem by applying ESWT with local anesthesia [32,38-40]. However, it turned out that local anesthesia may block the action of ESWs on substance P nerve fibers [41], and repetitive ESWT without local anesthesia was demonstrated being more effective than repetitive ESWT with local anesthesia in the treatment of chronic plantar fasciopathy [42,43].

In summary, the problem that the desire for higher EFDs in ESWT is opposed by the painfulness of the treatment has remained unsolved.

Mode of action of pulsed lasers with wavelength of 904 nanometers on musculoskeletal tissue

Already more than 30 years ago it was demonstrated that treatment with a pulsed laser with a wavelength of 904 nanometers (hereafter: “904 nm pulsed laser treatment”) (GaAlAs semiconductor laser; peak power, 2 W; pulse width, 200 ns; frequency, 3040 Hz) is able to influence the firing rate of nociceptors and, thus, may have an analgesic effect [44]. To this end, the authors of [44] placed a thermostatically controlled thermal probe on the tongue of anesthetized cats and recorded activities of heat nociceptors in the tongue.

Increasing the temperature from 30°C to 53°C (Δ = 23°C) caused more firing of the nociceptors than increasing the temperature from 33°C to 47°C (Δ = 14°C). Laser pretreatment for respectively (i) one minute, (ii) three minutes, (iii) five minutes or (iv) ten minutes (i) had no effect on the firing rate of the nociceptors, (ii) reduced the firing rate of the nociceptors in the Δ = 14°C experiment but not the Δ = 23°C experiment, (iii) substantially reduced the firing rate of the nociceptors in both experiments and (iv) had no additional effect compared to laser pretreatment for five minutes [44].

Furthermore, prostaglandin E2 (PGE2) plays a central role in inflammation and feeling pain via inflammatory nociception [45]. Already 14 years ago it was demonstrated that 904 nm pulsed laser treatment (GaAs laser; peak power, 10 W; pulse width, 200 ns; frequency, 5000 Hz) can influence the concentration of peritendinous PGE2 in humans [46]. To this end, the authors of [46] placed a microdialysis membrane in the peritendinous tissue parallel to both Achilles tendons of subjects suffering from bilateral Achilles tendinitis. Then, both Achilles tendons were pretreated with the laser for three minutes. However, only one Achilles tendon each received active treatment, whereas the other Achilles tendon each received sham treatment. Immediately hereafter the subjects performed pain inducing exercises that aggravated their symptoms, and PGE2 concentrations in the peritendinous tissue were measured. On the side of sham laser pretreatment the following mean relative PGE2 concentrations were found: I1, 100%; I2, 102%; I3, 118%; I4, 102%; I5, 89%; I6, 87%; I7, 73%. Thus, active laser pretreatment reduced the relative PGE2 concentration in peritendinous tissue compared to baseline even during exercises that increased the PGE2 concentration in the same tissue after sham laser pretreatment.

Treatment of musculoskeletal disorders with 904 or 905 nm pulsed, high power laser therapy alone

As of today (December 27, 2020) 23 RCTs listed in the PEDro database described treatment of musculoskeletal disorders with 904 or 905 nm pulsed, high power laser therapy alone, including rotator cuff pathology, tennis elbow, carpal tunnel syndrome, knee osteoarthritis, myofascial pain syndrome, acute cervical pain, chronic nonspecific low back pain and fibromyalgia) [47-69] (Table 1). Twenty out of these 23 studies (87%) reported that laser therapy was superior to sham treatment or another treatment modality. Of note, both the total number of treatment sessions as well as the number of treatment sessions per week reported in these studies were substantially higher than the corresponding numbers reported for ESWT [3]. This may limit the attractiveness of 904 or 905 nm pulsed, high power laser therapy alone in treatment of musculoskeletal disorders to both therapists and patients. However, these studies indicate that ESWT and 904 or 905 nm pulsed, high power laser treatment may have synergistic effects that are currently unexplored.

Applicability of extracorporeal shock wave therapy with increased energy flux density after 905 nm pulsed, high power laser pretreatment

Colleagues in Germany, Switzerland and Spain who have started to perform 905 nm pulsed, high power laser pretreatment before performing rESWT have reported the possibility to increase the EFD of radial ESWs by up to 50% when waiting five minutes between laser pretreatment and rESWT, and up to 100% when waiting one hour between laser pretreatment and rESWT, compared to rESWT without laser pretreatment (Alexander Ablass, Thomas Maier, James P.M. Morgan, Antoni Morral, Peter Stiller, Felix Zimmermann; personal communications). This experience was obtained using a DolorClast high power laser (wavelength, 905 nm; peak power, 300 W; pulse width, 100 ns; frequency, 40 KHz) (Electro Medical Systems, Nyon, Switzerland) and a DolorClast rESWT device (Electro Medical Systems).

HYPOTHESIS

It is hypothesized here that in patients suffering from musculoskeletal disorders that can be treated with ESWT, pretreatment with a 904 or 905 nm pulsed, high power laser does not only allow to apply higher EFDs in subsequent ESWT but actually results in faster and/or better treatment outcome than ESWT without laser pretreatment. Accordingly, it is hypothesized here that (unlike local anesthesia) the combination of ESWT with 904 or 905 nm pulsed, high power...
laser pretreatment leads to synergistic effects and, thus, is superior to either treatment modality alone.

Table 1 | RCTs on 904 or 905 nm pulsed, high power laser treatment of various musculoskeletal disorders listed in the PEDro database [6].

| Indication                        | Study No. | No. of TS | No. of TS per week | Control treatment          | Outcomea |
|----------------------------------|-----------|-----------|--------------------|----------------------------|----------|
| Rotator cuff tendinopathy        | [47]      | 6         | 3                  | Sham laser                 | Laser > sham laser |
| Shoulder pain                    | [48]      | 10        | 5                  | Sham laser                 | Laser > sham laser |
| Tennis elbow                     | [49]      | 10        | 2-3                | Sham laser                 | Laser = sham laser |
| Tennis elbow                     | [50]      | 15        | 5                  | Sham laser                 | Laser = sham laser |
| Tennis elbow                     | [51]      | 10        | 2-3                | Sham laser                 | Laser > sham laser |
| Cervical myofascial pain         | [52]      | 10        | 5                  | Sham laser                 | Laser = sham laser |
| Cervical myofascial pain         | [53]      | 10        | 5                  | Sham laser                 | Laser > sham laser |
| Cervical myofascial pain         | [54]      | 12        | 3                  | Sham laser                 | Laser = sham laser |
| Shoulder myofascial pain         | [55]      | 10        | 5                  | Sham laser, ultrasound     | Laser > ultrasound > sham laser |
| Myofascial pain                  | [56]      | n.r.      | n.r.               | Sham laser                 | Laser = sham laser |
| Various tendinitis               | [57]      | 6         | 1-2                | Sham laser                 | Laser = sham laser |
| ATDG                             | [58]      | 9         | 3                  | Sham laser                 | Laser = sham laser |
| Acute cervical pain              | [59]      | 10        | 5                  | Sham laser                 | Laser = sham laser |
| Chronic low back pain            | [60]      | 10        | 5                  | Sham laser                 | Laser = sham laser |
| Chronic low back pain            | [61]      | 20        | 5                  | Laser without exercise     | Laser with exercise > laser without exercise |
| Carpal tunnel syndrome           | [62]      | 18-24     | 3                  | Sham laser                 | Laser > sham laser |
| Carpal tunnel syndrome           | [63]      | 10        | 5                  | Ultrasound                 | Laser > ultrasound |
| Carpal tunnel syndrome           | [64]      | 20        | 5                  | PMFT                       | Laser > PMFT    |
| Nonspecific knee pain            | [65]      | 12        | 3                  | Sham laser                 | Laser = sham laser |
| Knee osteoarthris                | [66]      | 12        | 3                  | Sham laser                 | Laser = sham laser |
| Knee osteoarthris                | [67]      | 9         | 3                  | Sham laser                 | Laser = sham laser |
| Fibromyalgia                     | [68]      | 10        | 5                  | Sham laser                 | Laser = sham laser |
| Muscle injury (single impact blunt trauma) early treatment | [69]      | 10        | 5                  | Sham laser                 | Laser = sham laser |

DISCUSSION

The hypothesis outlined above may serve as basis for a variety of preclinical and clinical studies in the future.

Preclinical studies should address the questions (i) why 904 or 905 nm pulsed, high power laser pretreatment may not cause antagonistic effects to ESWT, as local anesthesia does, and (ii) which synergistic, molecular and cellular mechanisms can be expected when combining ESWT with 904 or 905 nm pulsed, high power laser pretreatment.

With regard to the first question it is of note that a single exposure of the right distal femur of normal rabbits to 1500 focused ESWs with EFD = 0.9 mJ/mm² resulted in the periosteum of the exposed femur (compared to the periosteum of the unexposed left femur) in no alteration of the mean PGE2 concentration at six hours (H6), H24 and six weeks (W6) post exposure, but an increased mean substance P concentration at both H6 and H24 and a reduced mean substance P concentration at W6 post exposure [23]. Furthermore, the same animals had on average statistically significantly fewer neurons immunoreactive for substance P in the right dorsal root ganglion (DRG) L5 (exposed side) than in the left DRG L5 (unexposed side) at W6 post exposure, with no alteration in the mean total number of neurons in this DRG [70]. In contrast, treatment of a rat model of neuropathic pain (chronic constriction injury of the sciatic nerve with increased substance P levels in DRG L4-L6) with laser therapy (904 nm, GaAs laser; peak power, 70 mW; pulse width, 60 ns; frequency, 9500 Hz; 10 treatment sessions; interval between treatment sessions, 2 days; stimulation of nine points lasting 18 seconds each per treatment session) reduced the mean substance P level in DRGs L4-L6 to levels that were found in control animals but not further [71] (similar results were reported in [72]). Together with the fact that exposure of musculoskeletal tissue to ESWs can be very painful, whereas treatment with a 905 nm pulsed, high power laser is usually not painful (A. Ablass, T. Maier, J.P.M. Morgan, A. Morral; P. Stiller, F. Zimmermann, personal communications), these data indicate that ESWs and 904 or 905 nm pulsed, high power lasers may act on different molecular and cellular targets in the treated tissue which prevents negative mutual interaction.

With regard to the second question it should be mentioned that both radial ESWs and focused EWSs can stimulate fibroblasts [28,73] and activate satellite cells in skeletal muscle [29,74], whereas in a rat model of gastrocnemius muscle injury (single impact blunt trauma) early treatment with a 904 nm laser reduced the inflammatory response as well as overexpression of inducible nitric oxide synthase and increased collagen production induced by trauma [75]. Accordingly, the effects of ESWs may primarily accelerate regeneration of damaged muscle [29,74], whereas the effects of 904 or 905 nm laser treatment may primarily prevent the formation of scar tissue after muscle trauma in a synergistic
manner. Clinical studies should determine potential short-term and long-term benefits of the combination of ESWT with 904 or 905 nm pulsed, high power laser pretreatment. Short-term benefits may include faster improvement of subjective (pain etc.) and objective (range of motion etc.) clinical endpoints as well as patients’ satisfaction with the treatment procedure (less pain during ESWT); long-term benefits may include further improvement of subjective (pain etc.) and objective (range of motion etc.) clinical endpoints and/or longer lasting improvement (e.g., in treatment of knee osteoarthritis).

Conclusions

Combining ESWT with 904 or 905 nm pulsed, high power laser pretreatment may raise ESWT and its significance in physical and rehabilitation medicine to a new, previously unattained level, with immediate benefit for patients.

Abbreviations

DRG, dorsal root ganglion; EFD, energy flux density; EFD*, positive energy flux density; EFD-, negative energy flux density; ESWs, extracorporeal shock waves; ESWT, extracorporeal shock wave therapy; fESWT, focused extracorporeal shock wave therapy; H, hours; MPa, Megapascal; js, microsecond; P-, negative peak pressure; P+, positive peak pressure; RCT, randomized controlled trial; rESWT, radial extracorporeal shock wave therapy; W, weeks.

Acknowledgement

The author thanks Alexander Abbass, PT (Augsburg, Germany), Thomas Maier, PT (Unterschleißheim, Germany), James P.M. Morgan, PT (Nuremberg, Germany), Antoni Morrall, PT, PhD (Barcelona, Spain), Peter Stiller, MD (Augsburg, Germany) and Felix Zimmermann (Rheinfelden, Switzerland) for fruitful discussions and sharing their personal experience with the combination of fESWT with 905 nm pulsed, high power laser pretreatment.

Funding

This study did not receive external funding.

Availability of data and materials

All datasets used and analyzed in this study are presented in this report.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Alexander Abbass, Thomas Maier, James P.M. Morgan, Antoni Morrall, Peter Stiller and Felix Zimmermann have agreed to have their names included in personal communications in this paper.

Competing interests

The author has received research funding at LMU Munich and consulted (until December 31st, 2017) for Electro Medical Systems (Nyon, Switzerland). However, Electro Medical Systems had no role in study design, data collection, data analysis, data interpretation and writing of the report.

References

1. Schmitz C, Császár NB, Rompe JD, Chaves H, Furia JP. Treatment of chronic plantar fasciopathy with extracorporeal shock waves (review). J Orthop Surg Res 2013;8:31. doi: 10.1186/1749-799X-8-31.
2. Speed C. A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence. Br J Sports Med 2014;48(21):1538–42. doi: 10.1136/bjsports-2012-091961.
3. Schmitz C, Császár NB, Milz S, Schieker M, Maffulli N, Rompe JD, Furia JP. Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database. Br Med Bull 2015;116(1):115-38. doi: 10.1093/bmbld/ldv047.
4. Kertzman P, Császár NBM, Furia JP, Schmitz C. Radial extracorporeal shock wave therapy is efficient and safe in the treatment of fracture nonunions of superficial bones: a retrospective case series. J Orthop Surg Res 2017;12(1):164. doi: 10.1186/s13018-017-0667-z.
5. Reilly JM, Bluman E, Tenforde AS. Effect of shockwave treatment for management of upper and lower extremity musculoskeletal conditions: a narrative review. PM&R 2018;10(12):1385-1403. doi: 10.1016/j.pmrj.2018.05.007.
6. Herbert R, Moseley A, Sherrington C. PEDro: a database of randomised controlled trials in physiotherapy. Health Inf Manag 1998;28(4):186-188. doi: 10.1177/18333589982800410.
7. Rompe JD, Furia J, Weil L, Maffulli N. Shock wave therapy for chronic plantar fasciopathy. Br Med Bull 2007;81-82:183-208. doi: 10.1093/bmbld/ldm005.
8. Sternecker K, Geist J, Beggel S, Dietz-Laursonn K, de la Fuente M, Frank HG, Furia JP, Milz S, Schmitz C. Exposure of zebra mussels to extracorporeal shock waves demonstrates formation of new mineralized tissue inside and outside the focus zone. Biof Open 2018;7(7):bio033258. doi: 10.1242/bio.033258.
9. Ogden JA, Töth-Kischkat A, Schultheiss R. Principles of shock wave therapy. Clin Orthop Relat Res 2001;(387):8-17.
10. Gerdesmeyer L, Maier M, Haake M, Schmitz C. Physikalisch-technische Grundlagen der extrakorporalen Stoßwellentherapie (ESWT) [Physical-technical principles of extracorporeal shockwave therapy (ESWT)]. Orthopade 2002;31(7):610-617. German. doi: 10.1007/s00132-002-0319-8.
11. Császár NB, Angstman NB, Milz S, Sprecher CM, Kobel P, Farhat M, Furia JP, Schmitz C. Radial shock wave devices generate cavitation. PLoS One 2015;10(10):e0140541. doi: 10.1371/journal.pone.0140541.
12. Angstman NB, Kiessling MC, Frank HG, Schmitz C. High interindividual variability in dose-dependent reduction in speed of movement after exposing C. elegans to shock waves. Front Behav Neurosci 2015;9:12. doi: 10.3389/fnbeh.2015.00012.
13. Schelling G, Delius M, Gschwender M, Grafe P, Gambihler S. Extracorporeal shock waves stimulate frog sciatic nerves indirectly via a cavitation-mediated mechanism. Biophys J 1994;66(1):133-140. doi: 10.1016/S0006-3495(94)80758-1.
14. Cleveland RO, Chitnis PV, McClure SR. Acoustic field of a ballistic shock wave therapy device. Ultrasound Med Biol 2007;33(8):1327-1335. doi: 10.1016/j.ultrasmedbio.2007.02.014.
15. Perez C, Chen H, Matula TJ, Karzova M, Khokhlova VA. Acoustic field characterization of the Duolith: measurements and modeling of a clinical shock wave therapy device. J Acoust Soc Am 2013;134(2):1663-1674. doi: 10.1121/1.4812885.
16. Cleveland RO, Lifshitz DA, Connors BA, Evan AP, Willis LR, Crum LA. In vivo pressure measurements of lithotripsy shock waves in pigs. Ultrasound Med Biol 1998;24(2):293-306. doi: 10.1016/s0301-5629(97)00270-6.
17. Maier M, Schmitz C. Shock wave therapy: what really matters. Ultrasound Med Biol 2008;34(11):1868-1869; author reply 1869-70. doi: 10.1016/j.ultrasmedbio.2008.03.016.
18. Foreman JC. Peptides and neurogenic inflammation. Br Med Bull. 1987 Apr;43(2):386–400. doi: 10.1093/oxfordjournals.bmb.a072189.
19. Sann H, Pierau FK. Efferent functions of C-fiber nociceptors. Z
Rheumatol 1998;57 Suppl 2:8-13. doi: 10.1007/s002930050226.

20. Snijderelaar DG, Dirksen R, Slappendel R, Crul BJ. Substance P. Eur J Pain 2000;4(2):121-35. doi: 10.1016/s0969-8046(00)00171.

21. Uchio Y, Ochi M, Ryoke K, Sakai Y, Ito Y, Kuwata S. Expression of neuroepitopes and cytokines at the extensor carpi radialis brevis muscle origin. J Shoulder Elbow Surg 2002;11(6):570-575. doi: 10.1067/mseg.2002.126769.

22. Andersson G, Backman LJ, Scott A, Lorentzon R, Forsgren S, Danielson P. Substance P accelerates hypercellularity and angiogenesis in tendon tissue and enhances paratendinitis in response to Achilles tendon overuse in a tendinopathy model. Br J Sports Med 2011;45(13):1017-22. doi: 10.1136/bjsm.2010.082750.

23. Maier M, Averbeck B, Milz S, Refior HJ, Schmitz C. Substance P and prostaglandin E2 release after shock wave application to the rabbit femur. Clin Orth Relat Res 2003;(406):237-245. doi: 10.1097/01.blo.0000030173.56585.8f.

24. Wang CJ. An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J 2003;26(4):220-232.

25. Wang FS, Yang KD, Kuo YR, Wang CJ, Sheen-Chen SM, Huang HC, Chen YJ. Temporal and spatial expression of bone morphogenetic proteins in extracorporeal shock wave-promoted healing of segmental defect. Bone 2003;32(4):387-396. doi: 10.1016/s8756-3282(03)00029-2.

26. Contaldo C, Högger DC, Khorrani Borozadi M, Stotz M, Platz U, Forster N, Lindenblatt N, Giovanoli P. Radial pressure waves mediate apoptosis and functional angiogenesis during wound repair in ApoE deficient mice. Microvasc Res 2012;84(1):24-33. doi: 10.1016/j.mvr.2012.03.006.

27. Hofmann A, Ritz U, Hessmann MH, Alini M, Rommens PM, Rompe JD. Extracorporeal shock wave-mediated changes in proliferation, differentiation, and gene expression of human osteoblasts. J Trauma 2008;65(6):1402-1410. doi: 10.1097/TA.0b013e182717ec2.

28. Hochstrasser T, Frank HG, Schmitz C. Dose-dependent and cell type-specific cell death and proliferation following in vitro exposure to radial extracorporeal shock waves. Sci Rep 2016;6:30637. doi: 10.1038/srep30637.

29. Mattyasovszky SG, Langendorf EK, Ritz U, Schmitz C, Schmidtmann I, Nowak TE, Wagner D, Hofmann A, Rommens PM, Drees P. Exposure to radial extracorporeal shock waves modulates viability and gene expression of human skeletal muscle cells: a controlled in vitro study. J Orth Surg Res 2018;13(1):75. doi: 10.1186/s13018-018-0779-0.

30. Chow IH, Cheing GL. Comparison of different energy densities of extracorporeal shock wave therapy (ESWT) for the management of chronic heel pain. Clin Rehabil 2007;21(2):131-141. doi: 10.1177/0269215506069244.

31. Vavken P, Holinka J, Rompe JD, Dorotka R. Focused extracorporeal shock wave therapy in calcifying tendinitis of the shoulder: a meta-analysis. Sports Health. 2009;1(2):137-144. doi: 10.1177/1941738108331197.

32. Park KD, Lee WY, Park MH, Ahn JK, Park Y. High- versus low-energy extracorporeal shock-wave therapy for myofascial pain syndrome of upper trapezius: A prospective randomized single blinded pilot study. Medicine. 2018;97(28):e11432. doi: 10.1097/MD.0000000000011432.

33. Gerdesmeyer L, Wagenpfeil S, Haake M, Maier M, Loew M, Wörtler K, Lampe R, Seil R, Handle G, Gassel S, Rompe JD. Extracorporeal shock wave therapy for the treatment of chronic calcifying tendinitis of the rotator cuff: a randomized controlled trial. JAMA 2003;290(19):2573-80. doi: 10.1001/jama.290.19.2573.

34. Zhang YF, Liu Y, Chou SW, Weng H. Dose-related effects of radial extracorporeal shock wave therapy for knee osteoarthritis: a randomized controlled trial. J Rehab Med 2020: Epub ahead of print. doi: 10.2340/16501977-2782.

35. Kvalvaag E, Brox JI, Engbretsen KB, Soberg HL, Juel NG, Bautz-Holler E, Sandvik L, Roe C. Effectiveness of radial extracorporeal shock wave therapy (reswt) when combined with supervised exercises in patients with subacromial shoulder pain: a double-masked, randomized, sham-controlled trial. Am J Sports Med 2017;45(11):2547-2554. doi: 10.1177/0005109017707505.

36. Yang TH, Huang YC, Lau YC, Wang LY, efficacy of radial extracorporeal shock wave therapy on lateral epicondylitis, and changes in the common extensor tendon stiffness with pretherapy and posttherapy in real-time sonoelastography: a randomized controlled study. Am J Phys Med Rehabil 2017;96(2):93-100. doi: 10.1097/PHM.0000000000000547.

37. Muthukrishnan R, Rashid AA, Al-Alkharji F. The effectiveness of extracorporeal shockwave therapy for frozen shoulder in patients with diabetes: randomized control trial. J Phys Ther Sci 2019;31(7):493-497. doi: 10.1589/jpts.31.493.

38. Haake M, Deike B, Thon A, Schmitz J. Exact focusing of extracorporeal shock wave therapy for calcifying tendinopathy. Clin Orthop Relat Res 2002;397(3):323-331. doi: 10.1097/00003086-200204000-00037.

39. Galasso O, Amelio E, Riccelli DA, Gasparini G. Short-term outcomes of extracorporeal shock wave therapy for treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo-controlled trial. BMC Musculoskelet Disord 2012;13:86. doi: 10.1186/1477-780x-13-86.

40. Wang CJ, Wang FS, Yang KD, Weng LH, Ko JY. Long-term results of extracorporeal shockwave treatment for plantar fasciitis. Am J Sports Med 2006;34(4):592-596. doi: 10.1177/0363546506065281.

41. Klonischinski T, Ament SJ, Schleerth T, Rompe JD, Birklein F. Application of local anesthesia inhibits effects of low-energy extracorporeal shockwave therapy (ESWT) on nociceptors. Pain Med 2011;12(10):1532-1537. doi: 10.1111/j.1536-5087.2011.01229.x.

42. Labek G, Auersperg V, Ziernhöld M, Poulios N, Böhner M. Einfluss von Lokalanästhesie und Energieflussdichte bei niederenergetischer Extrakorporaler Stosswellentherapie der chronischen Plantaren Fasziitis – Eine prospektiv-randomisierte klinische Studie [Influence of local anesthesia and energy level on the clinical outcome of extracorporeal shock wave-treatment of chronic plantar fasciitis]. Z Orthop Ihre Grenzgeb 2005;143(2):240-246. German. doi: 10.1055/s-2004-832379.

43. Rompe JD, Meurer A, Nafe B, Hofmann A, Gerdesmeyer L. Repetitive low-energy shock wave application without local anesthesia is more efficient than repetitive low-energy shock wave application with local anesthesia in the treatment of chronic plantar fasciitis. J Orthop Res 2005;23(4):931-941. doi: 10.1016/j.jores.2004.09.003.

44. Mezawa S, Iwata K, Naito K, Kamogawa H. The possible analgesic effect of soft-laser irradiation on heat nociceptors in the cat tongue. Arch Oral Biol 1988;33(9):693-694. doi: 10.1016/0003-9969(88)90125-2.

45. Momin A, McNaughton PA. Regulation of firing frequency in nociceptive neurons by pro-inflammatory mediators. Exp Brain Res 2009;196(1):45-52. doi: 10.1007/s00221-009-1744-2.

46. Bjordal JM, Lopes-Martins RA, Iversen VV. A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations. Br J Sports Med 2006;40(1):76-80. doi: 10.1136/bjsm.2005.020842.

47. England S, Farrell AJ, Copcock JS, Struthers G, Bacon PA. Low power laser therapy of shoulder tendinosis. Scand J Rheumatol
59. Emanet SK, Altan LI, Yurtkuran M. Investigation of the effect of GaAs laser therapy on cervical myofascial pain syndrome. Photomed Laser Surg 2010;28(3):397-403. doi: 10.1089/pho.2009.2555.

60. Haker E, Lundeberg T. Is low-energy laser treatment effective in lateral epicondylalgia? J Pain Symptom Manage 1991;6(4):241-246. doi: 10.1016/0885-8952(91)90104-u.

61. Altan L, Bingöl U, Aykaç M, Yurtkuran M. Investigation of the effect of GaAs laser therapy on cervical myofascial pain syndrome. Rheumatol Int 2005;25(1):23-27. doi: 10.1007/s00296-003-0396-y.

62. Gur A, Sarac AJ, Cevik R, Altimdag O, Sarac S. Efficacy of 904 nm gallium arsenide low level laser therapy in the management of chronic myofascial pain in the neck: a double-blind and randomize-controlled trial. Lasers Surg Med 2004;35(3):229-235. doi: 10.1002/lsm.20082.

63. Ceccherelli F, Altafini L, Lo Castro G, Avila A, Ambrosio F, Giron GP. Diode laser in cervical myofascial pain: a double-blind study versus placebo. Clin J Pain 1989;5(4):301-304. doi: 10.1097/00002508-198912000-00005.

64. Rayegani S, Bahrami M, Samadi B, Sedighipour L, Mokhtarirad M, Eliaspoor D. Comparison of the effects of low energy laser and ultrasound in treatment of shoulder myofascial pain syndrome: a randomized single-blinded clinical trial. Eur J Phys Rehabil Med 2011;47(3):381-389.

65. Olavi A, Pekka R, Perti K, Pekka P. Effects of the infrared laser therapy at treated and non-treated trigger points. Acupunt Electrother Res 1989;14(1):9-14. doi: 10.3727/036012989816358560.

66. Logdberg-Andersson M, Mutzell S, Hazel A. Low level laser therapy (LLLT) of tendinitis and myofascial pains -- a randomized double-blind, controlled study. Laser Ther 1997;9(2):79-86. doi: 10.5978/slsm.9.79.

67. Bertolucci LE, Grey T. Clinical analysis of mid-laser versus placebo treatment of arthalgic TMJ degenerative joints. Cranio 1995;13(1):26-29. doi: 10.1080/08869634.1995.11678038.

68. Soriiano F, Rios R, Pedrola M, Giagnorio J, Battagliotti CR. Acute cervical pain is relieved with Gallium Arsenide (GaAs) laser radiation. A double blind preliminary study. Laser Ther 1996;8(2):149-154. doi: 10.5978/slsm.8.149.

69. Soriiano F, Rios R. Gallium arsenide laser treatment of chronic low back pain: a prospective, randomized and double blind study. Laser Ther 1998;10(4):175-180. doi: 10.5978/slsm.10.175.

70. Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M. Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain. Lasers Surg Med 2003;32(3):233-238. doi: 10.1002/lsm.10134.

71. Naeser MA, Hahn KA, Lieberman BE, Branco KF. Carpal tunnel syndrome pain treated with low-level laser and microamperes transcutaneous electric nerve stimulation: A controlled study. Arch Phys Med Rehabil 2002;83(7):978-988. doi: 10.1016/j.amr.2002.33096.

72. Dincer U, Cakar E, Kiralp MZ, Kilac H, Dursun H. The effectiveness of conservative treatments of carpal tunnel syndrome: splinting, ultrasound, and low-level laser therapies. Photomed Laser Surg 2009;27(1):119-125. doi: 10.1089/pho.2008.2211.